16 completed, 7 terminated, 4 unknown, 3 withdrawn. 17 Phase 1, 14 Phase 2, 6 Not applicable, 4 Phase 3.
Follow Flucytosine: new trials by email Literature Review of Flucytosine trials Research Report on Flucytosine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST) Liposomal Amphotericin B (LAmB), Flucytosine (5FC), Flucytosine (5FC) placebo pill - Talaromycosis | Phase 3 | Not yet recruiting | Duke University | 428 | 2026-11-01 | 2026-09-21 |
| DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma DB107-RRV, DB107-FC, Radiation Therapy (RT) - High Grade Glioma, MGMT-Unmethylated Glioblastoma | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 70 | 2025-01-08 | 2026-03-11 |
| DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma DB107-RRV, DB107-FC - High Grade Glioma, Anaplastic Astrocytoma | Phase 2 | Recruiting | Ashish Shah | 33 | 2024-05-01 | 2026-05-28 |
| Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis AMBITION trial control, Flucytosine - Cryptococcal Meningitis | Phase 2 | Completed | University of Minnesota | 48 | 2024-04-09 | 2025-08-27 |
| Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis Amphotericin B Colloidal Dispersion, flucytosine, fluconazole - Cryptococcal Meningitis | Not applicable | Unknown | Peking Union Medical College Hospital | 30 | 2022-08-22 | 2022-07-22 |
| A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal Tract TMV-018 + 5-FC, TMV-018 + anti-PD-1, TMV-018 + 5-FC + anti-PD-1 - Gastrointestinal Cancer | Phase 1 | Withdrawn | Themis Bioscience GmbH | 2020-11-23 | 2020-11-25 | |
| Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week - Cryptococcal Meningitis | Completed | University of Pharmacy, Yangon | 30 | 2020-10-01 | 2022-04-21 | |
| Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer TG6002, Flucytosine (5-FC) - Colorectal Neoplasms | Phase 1 / Phase 2 | Terminated | Transgene | 15 | 2020-01-17 | 2023-06-23 |
| AmB Dose for Cryptococcal Meningitis Amphotericin B, Flucytosine - Cryptococcal Meningitis, HIV Infections | Phase 3 | Unknown | Shanghai Public Health Clinical Center | 40 | 2020-01-02 | 2019-10-29 |
| A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8) Toca 511, Toca FC (extended-release formulation of flucytosine) - Bladder Cancer | Phase 1 | Withdrawn | Tocagen Inc. | 2019-12-01 | 2020-03-30 | |
| Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. TG6002, Flucytosine (5-FC, Ancotil) - Colorectal Neoplasm, Digestive System Neoplasm | Phase 1 / Phase 2 | Terminated | Transgene | 51 | 2018-10-16 | 2023-06-23 |
| Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma ON-01, ONF - Glioblastoma Multiforme, Gliomas, Malignant | Phase 1 / Phase 2 | Completed | Beijing Neurosurgical Institute | 38 | 2018-08-01 | 2024-08-20 |
| Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®) - Glioblastoma, Brain Cancer | Phase 1 / Phase 2 | Unknown | Assistance Publique - Hôpitaux de Paris | 78 | 2017-10-12 | 2017-11-06 |
| A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care Toca 511, Toca FC - Newly Diagnosed High Grade Glioma (HGG) | Phase 1 | Withdrawn | Tocagen Inc. | 2017-01-01 | 2020-03-30 | |
| A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) Toca 511, Toca FC - Colorectal Cancer, Triple Negative Breast Cancer | Phase 1 | Terminated | Tocagen Inc. | 21 | 2016-07-01 | 2020-02-07 |
| The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Toca 511, Toca FC, Lomustine - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 2 / Phase 3 | Terminated | Tocagen Inc. | 403 | 2015-11-30 | 2020-02-07 |
| Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas E. coli CD-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium - Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma | Phase 1 | Completed | City of Hope Medical Center | 16 | 2014-10-28 | 2026-11-03 |
| Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor Toca 511, Toca FC - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 | Completed | Tocagen Inc. | 17 | 2014-02-01 | 2018-05-21 |
| Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection Flucytosine and fluconazole, Fluconazole - Cryptococcal Infection Disseminated | Phase 2 | Terminated | Yale University | 6 | 2013-09-01 | 2021-09-29 |
| Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors APS001F, Flucytosine (5-FC), 10% maltose - Tumors, Neoplasms | Phase 1 / Phase 2 | Suspended | Anaeropharma Science, Inc. | 75 | 2012-09-01 | 2021-05-12 |
Showing 20 of 34. Sign in to see all of them.
Meningitis, Cryptococcal (13) · Glioblastoma (10) · Astrocytoma (9) · HIV Infections (9) · Glioma (8) · Brain Neoplasms (7) · Acquired Immunodeficiency Syndrome (6) · Cryptococcosis (6) · Meningitis (6) · Oligodendroglioma (6) · AIDS-Related Opportunistic Infections (5) · Colorectal Neoplasms (5) · Brain Diseases (2) · Gliosarcoma (2) · Urinary Bladder Neoplasms (2)
Tocagen Inc. (8) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Pfizer (3) · Transgene (3) · City of Hope Medical Center (2) · ANRS, Emerging Infectious Diseases (1) · Anaeropharma Science, Inc. (1) · Ashish Shah (1) · Assistance Publique - Hôpitaux de Paris (1) · Beijing Neurosurgical Institute (1) · Duke University (1) · InterMune (1) · Novartis Pharmaceuticals (1) · Peking Union Medical College Hospital (1) · Shanghai Public Health Clinical Center (1)
United States (19) · France (4) · China (3) · Canada (2) · Belgium (1) · Burma (1) · Burundi (1) · Côte d’Ivoire (1) · Germany (1) · Israel (1) · Kenya (1) · Peru (1) · Puerto Rico (1) · South Africa (1) · South Korea (1)
Asha Das, MD (4) · Jana Portnow (2) · Ana-Claire L Meyer, MD, MSHS (1) · Armstrong D (1) · Ashish Shah, MD (1) · David B Meya (1) · David R Boulware (1) · J Jacobson (1) · Jaime R Merchan, MD (1) · Judith K Kwasa, MBChB MMed (1) · Manish Aghi, MD, NS (1) · Mark A Jacobson, MD (1)
PMID 27252174, PMID 28177438, PMID 29322091, PMID 29735994, PMID 29762717, PMID 33119048, PMID 40795226
2015 (1), R21CA282543 (1), R21NS077858 (1)